基因组前列腺评分与PI-RADS v2对主动监测前列腺癌进展的预测价值
研究纳入加州大学旧金山分校主动监测的低/中危前列腺癌患者,评估OncotypeDx GPS与PI-RADS v2评分与活检升级风险的关系。结果显示GPS每增加5单位及PI-RADS 4或5分均与活检升级风险升高独立相关,GPS在临床协变量基础上提供额外预测价值。
要点
- GPS每增加5单位,活检升级风险显著增加(HR 1.28)。
- PI-RADS 5分较1-2分活检升级风险HR 4.38,4分较1-2分HR 2.62。
- GPS在临床协变量基础上对活检升级提供额外预测价值。
核心结论
- 较高的GPS或PI-RADS v2评分4或5分与主动监测患者活检升级风险增加相关。
研究设计与样本
- 回顾性队列研究,纳入加州大学旧金山分校主动监测的低/中危前列腺癌患者(PSA≤20 ng/ml,临床分期T1/T2,Gleason评分6),140例仅有GPS,169例仅有PI-RADS v2,131例两者均有。
主要发现
- GPS每增加5单位与活检升级风险增加相关(HR 1.28,95%CI 1.19-1.39,p<0.01)。
- PI-RADS 5分 vs 1-2分(HR 4.38,95%CI 2.36-8.16,p<0.01)和4分 vs 1-2分(HR 2.62,95%CI 1.45-4.76,p<0.01)均与活检升级风险增加相关。
- 在同时有GPS和PI-RADS v2的患者亚组中,GPS与活检升级相关,并在临床协变量基础上增加预测价值(偏似然比p=0.01)。
关键数值与推荐
- 活检升级定义为Gleason评分从3+3增至3+4或更高。
- GPS每5单位HR 1.28(95%CI 1.19-1.39,p<0.01)。
- PI-RADS 5 vs 1-2 HR 4.38(95%CI 2.36-8.16,p<0.01);4 vs 1-2 HR 2.62(95%CI 1.45-4.76,p<0.01)。
临床怎么用
- 对于主动监测的低/中危前列腺癌患者,GPS和PI-RADS v2评分可用于辅助评估活检升级风险。
- GPS与PI-RADS v2联合使用可能优化风险分层,但需结合临床因素综合判断。
局限性
- 回顾性研究设计,样本来自单一机构,可能存在选择偏倚。
- 部分患者仅有GPS或仅有PI-RADS v2数据,联合分析亚组样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The OncotypeDx® GPS (Genomic Prostate Score®) is a 17-gene RNA expression assay intended to help guide treatment decisions in men diagnosed with prostate cancer. The PI-RADS™ (Prostate Imaging Reporting and Data System) version 2 was developed to standardize the risk stratification of lesions identified on multiparametric prostate magnetic resonance imaging. We sought to determine whether these tests are associated with an increased risk of biopsy upgrading in men on active surveillance. MATERIALS AND METHODS: We identified all patients on active surveillance at the University of California-San Francisco who had low/intermediate risk prostate cancer (prostate specific antigen 20 ng/ml or less and clinical stage T1/T2) and Gleason score 6 disease who underwent multiple biopsies and had a GPS available and/or had undergone multiparametric prostate magnetic resonance imaging with an available PI-RADS version 2 score. The primary study outcome was biopsy upgrading, defined as an increase in the Gleason score from 3 + 3 to 3 + 4 or greater, which was analyzed by Cox proportional hazards regression. RESULTS: Of the men 140 had only GPS test findings, 169 had only a PI-RADS version 2 score and 131 had both data. Each 5-unit increase in the GPS was associated with an increased risk of biopsy upgrading (HR 1.28, 95% CI 1.19-1.39, p <0.01). PI-RADS scores of 5 vs 1-2 (HR 4.38, 95% CI 2.36-8.16, p <0.01) and 4 vs 1-2 (HR 2.62, 95% CI 1.45-4.76, p <0.01) were also associated with an increased risk of a biopsy upgrade. On subanalysis of patients with GPS and PI-RADS version 2 scores the GPS was associated with biopsy upgrading, adding value to the clinical covariates (partial likelihood ratio p = 0.01). CONCLUSIONS: A higher GPS or a PI-RADS version 2 score of 4 or 5 was associated with an increased risk of biopsy upgrading.
引用
- Kornberg Z, Cowan JE, Westphalen AC, et al. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance. J Urol. 2019. PMID: 30179620. doi:10.1016/j.juro.2018.08.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。